Rapafusyn
Baltimore, US · 1 known investors
Rapafusyn develops molecular glue therapeutics using its RapaGlue platform of non-degrading macrocyclic compounds designed to modulate hard-to-drug intracellular and transmembrane protein targets. Its AI-enabled discovery approach and DNA-encoded library support an early-stage pipeline across oncology, immunology and inflammation, and renal disease, including a lead program in acute kidney injury.</parameter> <parameter name="hq_city">Baltimore
Founders & leadership
JO
Jun O. LiuFounder
Investors · 1
Frequently asked questions
- What does Rapafusyn do?
- Rapafusyn develops molecular glue therapeutics using its RapaGlue platform of non-degrading macrocyclic compounds designed to modulate hard-to-drug intracellular and transmembrane protein targets. Its AI-enabled discovery approach and DNA-encoded library support an early-stage pipeline across oncology, immunology and inflammation, and renal disease, including a lead program in acute kidney injury.</parameter> <parameter name="hq_city">Baltimore
- Who founded Rapafusyn?
- Rapafusyn was founded by Jun O. Liu.
- Who are Rapafusyn's investors?
- Rapafusyn's investors include 3E Bioventures Capital.
- Where is Rapafusyn headquartered?
- Rapafusyn is headquartered in Baltimore, US.